Sonrotoclax · Beqalzi

Small molecule

Also known as BGB-11417

Acceleratedapproval

Evidence outlook

Accelerated approval: Mantle Cell Lymphoma

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT05471843 · Phase 1/2 · met primary endpoint · grade pending

Also in development:Acute Myeloid Leukemia · Phase 2Chronic Lymphocytic Leukemia · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Phase 2/3 (1)
Other / comorbidity
NCT07932873 · The Affiliated People's Hospital of Ningbo University
2028-09-01 – 2028-12-01 · MDS (Myelodysplastic Syndrome)
What this study did
Phase 2 (25)
Acute Myeloid Leukemia
NCT07548710 · Ruijin Hospital
2026-05-01 – 2028-12-21 · Acute Myeloid Leukemia
What this study did
NCT07937124 · First Affiliated Hospital of Zhejiang University
2026-12-15 – 2028-12-14 · Acute Myeloid Leukemia
What this study did
Chronic Lymphocytic Leukemia
NCT07508995 · M.D. Anderson Cancer Center
2026-08-20 – 2033-07-01 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT07887061 · Fred Hutchinson Cancer Center
2027-01-01 – 2032-07-01 · Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT06839053 · Fred Hutchinson Cancer Center
2025-06-02 – 2032-07-01 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT07671378 · The First Affiliated Hospital with Nanjing Medical University
2026-06-01 – 2030-12-31 · CLL (Chronic Lymphocytic Leukemia)
What this study did
NCT06367374 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-30 – 2030-07-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06849713 · Massachusetts General Hospital
2025-05-16 – 2030-03-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
What this study did
NCT06637501 · BeOne Medicines
2024-11-14 – 2029-09 · Chronic Lymphocytic Leukemia
What this study did
NCT07674810 · M.D. Anderson Cancer Center
2026-12-31 – 2029-04-30 · Chronic Lymphocytic Leukemia
What this study did
NCT07812246 · City of Hope Medical Center
2027-08-04 – 2028-08-13 · Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT05479994 · BeiGene
2022-10-25 – 2027-08-25 · Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia
What this study did
Mantle Cell Lymphoma
NCT07341191 · Canadian Cancer Trials Group
2026-08-24 – 2030-12-31 · Mantle Cell Lymphoma
What this study did
NCT07944651 · Tianjin Medical University Cancer Institute and Hospital
2026-12-08 – 2030-12-08 · Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
What this study did
NCT07799220 · Memorial Sloan Kettering Cancer Center
2026-12 – 2028-09 · Mantle Cell Lymphoma
What this study did
Other / comorbidity
NCT07682415 · Yi Shuhua
2026-06-08 – 2034-08-01 · CLL / SLL
What this study did
NCT06547866 · French Innovative Leukemia Organisation
2025-12-01 – 2031-12-31 · Waldenstrom Macroglobulinemia
What this study did
NCT07774234 · The First Affiliated Hospital of Soochow University
2026-08-20 – 2030-08-20 · Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma
What this study did
NCT06463691 · Tianjin Medical University Cancer Institute and Hospital
2024-08-01 – 2029-07 · MCL
What this study did
NCT07335887 · Peking University People's Hospital
2026-02-10 – 2028-08-31 · AL Amyloidosis (AL), t(11;14) Positive
What this study did
NCT05952037 · BeOne Medicines
2023-10-23 – 2028-08 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
What this study did
NCT04271956 · German CLL Study Group
2020-02-19 – 2027-08 · Richter Transformation
What this study did
Phase 1/2 (10)
Acute Myeloid Leukemia
NCT07770698 · BeOne Medicines
2026-12 – 2031-09 · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Relapsed, Pediatric ALL, Pediatric ALL, B Cell, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric AML, R/R AML, R/R B-cell ALL
What this study did
NCT07757672 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-01 – 2029-04-30 · AML (Acute Myelogenous Leukemia, HSCT
What this study did
Chronic Lymphocytic Leukemia
NCT06697184 · BeOne Medicines
2025-01-23 – 2032-11-30 · Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
What this study did
Mantle Cell Lymphoma
Other / comorbidity
NCT07885397 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-10-15 – 2029-12-31 · Myelodysplastic Syndromes, High Risk
What this study did
NCT06634589 · BeOne Medicines
2024-11-27 – 2029-12-02 · B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
What this study did
NCT07687004 · Institute of Hematology & Blood Diseases Hospital, China
2026-08-01 – 2029-08-01 · Multiple Myeloma (MM)
What this study did
NCT07638787 · Ruijin Hospital
2026-06-15 – 2029-04-30 · Large B-cell Lymphoma
What this study did
Phase 1 (9)
Chronic Lymphocytic Leukemia
NCT06859008 · City of Hope Medical Center
2025-08-25 – 2029-01-31 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
What this study did
Mantle Cell Lymphoma
NCT07548255 · Ruijin Hospital
2026-04-20 – 2029-03-01 · Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety
What this study did
Other / comorbidity
NCT04277637 · BeOne Medicines
2020-03-24 – 2027-05-31 · Mature B-Cell Malignancies
What this study did
NCT07855991 · BeOne Medicines
2026-11 – 2027-02-08 · Hepatic Impairment, Healthy Adult Participants
What this study did
NCT07628881 · BeOne Medicines
2026-06-17 – 2026-09-26 · Healthy Volunteers
What this study did
NCT04883957 · BeiGene
2021-07-05 – 2026-09-01 · Mature B-cell Malignancies
What this study did
NCT06543043 · BeiGene
2024-08-19 – 2024-11-07 · Not Determined
What this study did
NCT05844111 · BeiGene
2023-05-22 – 2023-06-18 · Healthy Volunteers
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sonrotoclax (Beqalzi): this drugPhase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
FCN-338
Phase 2(overall)
Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
OrcaGraft (Orca-Q)Phase 1/2Cell therapyTreg-enriched allogeneic haematopoietic stem cell graftnot yet gradedNo reviewed efficacy summary in this indication
RogocekibPhase 1/2Small moleculeCLK (CDC-like kinase family)not yet gradedNo reviewed efficacy summary in this indication
Surzetoclax
Phase 1/2(overall)
Small moleculeBCL-2
not yet graded(overall)
No reviewed efficacy summary in this indication
TGRX-814Phase 1/2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
BGB-21447
Phase 1(overall)
Small moleculeBCL-2
not yet graded(overall)
No reviewed efficacy summary in this indication
FXS0683Phase 1Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
LonitoclaxPhase 1Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
LOXO-338
Discontinued
Small moleculeBCL-2
Weak signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 70 furthest-along competitors are listed; 63 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(42 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Beqalzi (Sonrotoclax) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (2)
Phase 1/2Relapsed/Refractory Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-11 · NCT06637501 · CT.gov ↗
What to watch
2027 (11)
February 2027 (1)
Phase 1Hepatic Impairment, Healthy Adult ParticipantsNot yet recruiting
Est. primary completion 2027-02-08 · NCT07855991 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-04-30 · NCT07674810 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1Mature B-Cell MalignanciesActive not recruiting
Est. primary completion 2027-05-31 · NCT04277637 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Richter TransformationRecruiting
Est. primary completion 2027-08 · NCT04271956 · CT.gov ↗
What to watch
Phase 1/2Multiple Myeloma (MM)Not yet recruiting
Est. primary completion 2027-08-01 · NCT07687004 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Large B-cell LymphomaNot yet recruiting
Est. primary completion 2027-09-30 · NCT07638787 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-10-31 · NCT06497062 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1/2Myelodysplastic Syndromes, High RiskRecruiting
Est. primary completion 2027-12-31 · NCT07885397 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07671378 · CT.gov ↗
What to watch
Phase 2AL Amyloidosis (AL), t(11;14) PositiveRecruiting
Est. primary completion 2027-12-31 · NCT07335887 · CT.gov ↗
What to watch
2028 (14)
March 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT06849713 · CT.gov ↗
What to watch
August 2028 (4)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-08-01 · NCT06839053 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2028-08-13 · NCT07812246 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-08-31 · NCT04771130 · CT.gov ↗
What to watch
Phase 3Mantle Cell LymphomaRecruiting
Est. primary completion 2028-08-31 · NCT06742996 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-09 · NCT07799220 · CT.gov ↗
What to watch
Phase 2/3MDS (Myelodysplastic Syndrome)Not yet recruiting
Est. primary completion 2028-09-01 · NCT07932873 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-09-30 · NCT07321652 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2MCLRecruiting
Est. primary completion 2028-12 · NCT06463691 · CT.gov ↗
What to watch
Phase 1/2B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell LymphomaRecruiting
Est. primary completion 2028-12-02 · NCT06634589 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-08 · NCT07944651 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-12-14 · NCT07937124 · CT.gov ↗
What to watch
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2028-12-31 · NCT06547866 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL), High-grade B-cell LymphomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07774234 · CT.gov ↗
What to watch
2029 (9)
January 2029 (2)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07899398 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT06859008 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2029-03-01 · NCT07548255 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-04-30 · NCT07757672 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-09-30 · NCT06943872 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-11-01 · NCT06854003 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-11-30 · NCT06697184 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07341191 · CT.gov ↗
What to watch
Phase 2CLL / SLLNot yet recruiting
Est. primary completion 2029-12-31 · NCT07682415 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2030-02-28 · NCT06367374 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-04-30 · NCT07770698 · CT.gov ↗
What to watch
2031 (3)
February 2031 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-02 · NCT07277231 · CT.gov ↗
What to watch
July 2031 (2)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2031-07-01 · NCT07887061 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-07-01 · NCT07508995 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2032-02 · NCT06073821 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 August 2025Topline resultPhase 1/2 BGB-11417-201 (NCT05471843) of sonrotoclax in R/R MCL met its primary endpoint
BeOne Medicines · Source ↗